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Ghrelin function in human obesity and type 2 diabetes: A concise review. 
Introduction
Type 2 diabetes mellitus (T2DM) and obesity are both chronic conditions associated with significant morbidity and mortality predominantly from associated chronic diseases. The World Health Organisation (WHO) states that obesity is a global epidemic, with over 1.9 billion obese adults.
Obesity results from the dysregulation of energy expenditure resulting in an accumulation of white adipose tissue due to adipogenesis or lipid retention 1 . Therefore, the function of adipocytes, which includes the secretion of various hormones linked to the modulation of metabolism, is central to the development of obesity. A key hormone of interest, that is known to regulate cell proliferation and lipid retention, is the gastrointestinal peptide ghrelin 2 . The focus of this article is to review the mechanism(s) underlying ghrelin mediated lipid retention in adipocytes and its relevance to the aetiology of T2DM. The identification of new molecules modulating ghrelin mediated lipid retention in adipose tissue may be a therapeutic strategy for improving glucose homeostasis associated with obesity and T2DM.
Ghrelin
In 1999, Masayasu Kojima first described a 28 amino acid peptide hormone located in the stomach, with a distinctive N-octanoylated serine 3 residue 2 . This peptide was named 'ghrelin', from the Latin word 'Ghre' which means 'grow' due to its role as a growth hormone releasing peptide 2, 3 . The novel peptide was isolated from the gut of both human and rat as the endogenous ligand of the growth hormone secretagogue receptor (GHS-R) 4 . GHS-R is transcribed in humans from the growth hormone receptor 1 (GHR1) gene, which encodes the full length functional receptor (GHS-R1α) and a splice variant truncated non-functional isoform (GHS-R1β) 5, 6 . GHS-R1α mRNA is expressed at low levels over a wide tissue distribution but it predominantly expressed in the anterior pituitary gland 5 .
The highest levels of ghrelin are secreted from the X/A-like cells of the oxyntic glands located in the gastric fundus, with lower levels widely distributed throughout the body 7, 8 . Ghrelin is secreted direct into the local gastric circulation and transported to the brain directly, requiring it to either cross the blood-brain barrier via a saturated transport system or via the blood stream to enter areas of the brain that are not protected by the blood brain barrier 9 . Ghrelin also modulates the hypothalamic arcuate nucleus (ARC), in an indirect manner, via activation of the vagus nerve and brain stem nuclei 9, 10 . Ghrelin circulates in two major forms; acylated (approximately 5% of total ghrelin) and desacyl (95% of total ghrelin) 11 . Previous work has demonstrated that the protein coding gene, membrane bound O-acyltransferase 4 (MBOAT4) is vital in the activation of ghrelin 12 .
The human gene, MBOAT4 is located on chromosome 8 (8p12) and contains 6 exons. MBOAT4 transcribes a protein that was later termed ghrelin O-acyltransferase (GOAT), as this is the only enzyme known to post translationally acylate ghrelin. Both forms of ghrelin are observed to cross the barrier in a blood to brain direction. However, desacyl-ghrelin had reduced ability in crossing the barrier in a brain-blood direction 13 . Ghrelin's ability to cross the blood-brain barrier is the result of a combination of three systems; non-saturable, saturable blood-brain transport and saturable brainblood transport, all of which are dependent on the unique post translational acylation and primary structure [13] [14] [15] . In the last 16 years research has demonstrated that ghrelin has various peripheral effects and caused a great interest into the manipulation of the ghrelin system as a pharmacological tool. Ghrelin has a homeostatic role that encompasses multiple areas of the body, with actions that include; downregulation of brown adipose tissue thermogenesis [16] [17] [18] , modulation of nonhypothalamic brain regions producing an increased taste sensation 19 and stimulation of gastric emptying and motility 6, 20 . The actions of ghrelin may contribute to the development of T2DM and obesity 6 however this review will focus, in detail, on three main sites of ghrelin action; the hypothalamus, adipose tissue and the pancreas ( Figure  1 ).
Ghrelin & the hypothalamus

Obesity
Ghrelin gene expression and plasma ghrelin levels change with food intake, such that in healthy humans acylated levels are elevated before feeding and decreased by feeding [21] [22] [23] . However, during prolonged fasting, plasma levels of acyl-ghrelin are not elevated and it is plasma desacyl-ghrelin levels that double 24, 25 . Indeed, ghrelin is the only known gastrointestinal hormone whose concentration is increased in the blood following calorie restriction. Ghrelin is often termed 'the hunger hormone' and is an appetite stimulatory peptide ghrelin and obesity with a main focus on plasma ghrelin levels being negatively correlated with body mass index (BMI) 29 . As well as in obese patients, total ghrelin levels are reduced in obese patients with T2DM and levels does not fluctuate throughout the day. Therefore, the total ghrelin concentration does not return to baseline level as it does in lean patients after feeding 11, 33, 34 . The obese state has attenuated ghrelin levels resulting in abnormal hunger scores, upon the administration of acyl-ghrelin in humans, hunger profiles within obese subjects are returned to that of lean subjects 35 . The supressed level of ghrelin within diet induced obesity (DIO) can be linked to the decline in the expression of ghrelin and MBOAT4 in the stomach and GHS-R expression in the hypothalamus of mice 36 . DIO also has a detrimental effect on the neuroendocrine ghrelin system and causes ghrelin resistance in rodents through the down regulation and dysfunction of NPY/ AGRP neurons 36 . The apparent species-dependent discrepancy in DIO-induced ghrelin resistance warrants further research and may prevent the ghrelin system being a useful therapeutic target in DIO 37 .
A role for ghrelin in human obesity?
Obesity is a multifactorial disease and its origin can span from various avenues including genetics. Zorrilla et al, demonstrated that ghrelin immunization through a vaccine approach produced a significant reduction in weight through metabolic efficiency rather than altering hyerphagia 40 .
Further immunizations were carried out through the use of Spiegelmers, a single stranded mirror image oglionucleotide which binds to ghrelin to decrease its half-life 37, 41 . However, the use of Spiegelmers only generated weight reduction on a short term basis 41 . Preventing the acylation of ghrelin through either the reduction in MBOAT4 transcription or GOAT function will allow for a decrease in circulating acyl-ghrelin. The use of an antagonist of the GHS-R, [D-Lys 3 ]GHRP-6, has been shown in male mice to allow for an increase in glycaemic control and decrease in body weight 42 . The reduction in glucose levels was mirrored by a decrease in insulin levels, indicating that GHS-R antagonism may be a therapeutic pathway for treating both obesity and insulin resistance 42, 43 .
Controversially, an antagonist is only efficacious when blocking the action of an agonist, yet, as previously mentioned, the low levels of circulating ghrelin present in obese subjects may invalidate this approach. However, further work has led to the development of GHS-R1α inverse agonists that work on the principle that GHS-R1α signals ~50% activity, independent of the presence of ghrelin 44 .
The following inverse agonists; [D-Arg-1, D-Phe5, D-Trp7,9, Leu 11]-substance P, which prevent constitutive GHS-R1α activity, were administered intracerebroventricularly in rats, resulting in a reduction in food intake and weight gain 45 . Han Lee, and colleagues also noted that the neuronal depletion of GHS-R abolished ghrelin-induced food intake and was detrimental to the development of DIO 46 . These finding indicate that GHS-R is a key modulator in energy metabolism and plays a role in DIO. We propose that further research is needed to elucidate the possible adipogenic and lipogenic role of constitutive GHS-R1α signalling in the context of human obesity.
Ghrelin & Adipocytes
Adipogenesis
Ghrelin is involved in the regulation of metabolic hormones, with GHS-R's present within adipose tissue 4, 47 . In addition to stimulating growth hormone (GH) secretion and appetite, ghrelin has been shown to play a role in adiposity. Adipogenesis is a regulated process involving the differentiation of pre-adipocytes into mature adipocytes. This is controlled by specific transcription factors; peroxisome proliferator-activated receptor γ (PPARγ) and sterol-regulatory element binding protein- . In the presence of acyl-ghrelin, mTORC1 and Akt/PKB can enhance PPARγ activation promoting adipogenesis 27 . The presence of mTORC1 and Akt/PKB highlights ghrelin's ability to have multifactorial effects, with the synergy of acyl-ghrelin's adipogenic effect and insulin signalling. Both desacyl and acyl-ghrelin produce an increase in adipogenesis and a decrease in insulin sensitivity, however desacyl-ghrelin's role is not consistent across studies (Table 1) 27
. The elevation of SREBF1 was accompanied by a significant increase in lipid accumulation in visceral adipocytes 11 . This administration of ghrelin directly stimulated intracytoplasmic lipid accumulation via the increased production of various fat storage promoting enzymes including carboxylase, acetyl CoA, fatty acid synthase and lipoprotein lipase 11 .
Lipid retention
Following chronic intravenous administration in mice, ghrelin has also been shown to increase mRNA expression of genes which promote the retention of cholesterol 49 . The reverse cholesterol transport pathway, the removal of excess cholesterol from peripheral tissues back to the liver for excretion and catabolism, is critical due to the pathways role in defence against atherosclerosis [50] [51] [52] . This cholesterol efflux is dependent upon the ATP binding cassette (ABC)A1 and ABCG1 50, 53 . ABCG1 and ABCA1 are members of a superfamily of transporters that functions to transport cholesterol to the cell surface for removal by high density lipoproteins (HDL) 50, 52 . PPARγ induces the expression of ABC via nuclear cholesterol sensors, liver X receptors (LXR) i.e. LXRα and LXRβ
52
. LXR acts as a transcription regulator for the genes associated with cholesterol efflux, which is activated when total cellular cholesterol levels are high 54 . However, when total cellular cholesterol levels are low, SREBP induces cholesterol biosynthesis 54 . So in the presence of ghrelin, SREBP1-c expression is increased whilst ABCG1 and LXRβ expression is decreased 49 . Even though these results indicate ghrelin has a role in increasing lipid retention within adipocytes, the relationship between cholesterol efflux, biosynthesis genes and ghrelin is disputed among studies. The hypothalamic activation of GHS-R1α in mice and rats results in the activation of Sirtuin 1 (SIRT1) to deacetylate the tumour suppressor gene p53, increasing phosphorylation of AMP-activated protein kinase (AMPK) which in turn inactivates fatty acid biosynthesis and activates fatty acid oxidation [55] [56] [57] . In vivo, administration of ghrelin to p53 null mice demonstrates a decrease in lipid metabolism modulating gene expression i.e. SREBP1c, indicating that p53 is essential for the action of ghrelin on adipose tissue 55 . Ghrelin administration has also been reported to activate the PPARγ-LXR-ABC pathway in a dose dependant manner, where ghrelin results in an increase in LXR and ABC expression in human THP-1 macrophages 58 . An increase within cellular fat mass could result in an increase in lipogenesis and substrate uptake and a decrease in lipolysis and export 1 . These processes could alter the intrinsic regulation of free fatty acids and cholesterol biosynthesis pathways that could lead to hypertriglyceridemia and other complications 59 . Due to the diversity of published data and various doses of acyl-ghrelin administered, further research into ghrelin mediated lipid retention especially within humans is needed.
Ghrelin & the pancreas
Glucose homeostasis
The process of glucose homeostasis is dependent on the liver and gut as sources for circulating glucose and adipose tissue as a peripheral organ for glucose utilisation. Ghrelin and GHS-R1α RNAs are expressed within the pancreas and β-cells, suggesting a possible relation for ghrelin in affecting glucose homeostasis via insulin function. In humans acyl-ghrelin has direct metabolic actions at a peripheral level, influencing endopancreatic function and altering glucose's diabetogenic action 60, 61 .
As well as acyl-ghrelin, desacyl-ghrelin has been shown to alter glucose metabolism, the intravenous administration of desacyl-ghrelin in humans has been demonstrated to promote a favourable influence on glucose metabolism, insulin sensitivity and the inhibition of lipolysis 60, 61 . The expression of GHS-R and ghrelin within the pancreas suggests local regulation of insulin secretion 62, 63 , with acyl-ghrelin supressing insulin secretion both in vivo and in vitro. Dezaki and colleagues 64 reported that endogenous acyl-ghrelin supresses insulin secretion via a restriction on glucose induced cytosolic calcium concentration and insulin release within islet β cells of mice and rats.
Furthermore, ghrelin inhibits glucose-induced membrane excitability, supressing cellular signalling 64 .
However, the mechanism in which acyl-ghrelin regulates pancreatic islet function remains unclear with few studies in humans. Ghrelin's role in the attenuation of glucose stimulated insulin secretion Studies in humans has shown that the acute intravenous administration of acyl-ghrelin via bolus injection and infusion are associated with an increase in plasma glucose levels in both healthy and obese patients, and this ghrelin mediated increase was seen to enhance second phase insulin response 8, 26, 66, 67 . In fasted mice this direct, non GH-mediated hyperglycaemic effect was blunted by the oral administration and intraperitoneal injection of a GHS-R antagonist, stabilising blood glucose levels 68 . Broglia et al 26 noted that acyl-ghrelin's initial stimulation of somatostatin levels caused an inhibition of insulin release. Further work by Arosio and colleagues 69 noted a similar relationship between acyl-ghrelin, somatostatin and glucose metabolism. However, the simultaneous rise in somatostatin and glucose indicates that ghrelin's effect on glucose metabolism is still unclear. The effect of ghrelin is suggested to be direct yet the query remains as to whether this effect is via the promotion of glycogen breakdown and/or the inhibition of glucose uptake. Upon longer term administration of acyl-ghrelin in healthy men, at a constant infusion rate lasting 180 minutes at 5 pmol/Kg, glucose levels were raised but glucose-induced insulin secretion was blocked, with the blockage only being restored when ghrelin supply ceased 70 . However, acyl-ghrelin infusion in healthy humans caused peripheral insulin resistance post administration raising the possibility that insulin resistance may be attributed to raised GH and free fatty acid (FFA) secretion 63 .
The literature indicates that acyl-ghrelin plays a detrimental role in glucose homeostasis, however studies indicate that desacyl-ghrelin plays a beneficiary role. In rodents and humans, desacyl-ghrelin was proven to enhance insulin levels in response to glucose load and shown to counteract acyl-ghrelins diabetogenic effect [71] [72] [73] . This a role for desacyl-ghrelin as a potent secretagogue reiterates the importance to consider desacyl and acyl-ghrelin as separate entities and a possible therapeutic pathway may lie within the desacyl-ghrelin and acyl-ghrelin ratio.
A role for ghrelin in type 2 diabetes?
An important contributor to the pathophysiology of T2DM is the failure of glucose uptake into the peripheral tissues such as adipose, skeletal muscle and liver. Decreased ghrelin levels within patients with T2DM are associated with an increase in abdominal adiposity and insulin resistance 74 . As
previously mentioned ghrelin has a demonstrated role in fat metabolism and glucose homeostasis, and cross talk between lipid and glucose metabolism may result in a physiological role for ghrelin in insulin resistance. Cellular lipid accumulation that is observed upon ghrelin administration will have a knock on effect on glucose homeostasis. There are two hypothesese in place regarding lipid mediated insulin resistance. The first is an excess of visceral adiposity triggers the release of FFA into the circulation. An increase in hepatic FFA oxidation triggers insulin resistance and an increase in glucose output from the liver 75, 76 . Acyl-ghrelin infusion in humans has been associated with a rise in circulating FFA levels 35 , this could result in a decrease in insulin sensitivity 76 . These findings suggest a causative role in the reported insulin resistance that occurs in healthy volunteers when given an acyl-ghrelin infusion 70, 77 . The second hypothesis is related to enlarged fat laden adipocytes associated with release of FFA, physical stress and reactive oxygen species (ROS) production 78, 79 .
Prolonged elevation of ghrelin increases visceral adiposity in mice and attenuates the transcription of LXRβ and ABCG1 which increases adipocyte volume due to a reduction in lipid export . Furthermore, acyl-ghrelin promotes new neurone formation and enhances cognition in the brains of adult rodents 87, 88 . With ghrelin reported to have effects on multiple organs in the body it is clear that new ghrelin-based therapies for T2DM need to consider potential adverse consequences, particularly for brain function.
Future work
In order to establish a possible therapeutic role for ghrelin within human obesity and T2DM previous research findings must be amalgamated and developed further to delineate ghrelin-specific pathways. The examination of the use GHS-R1α inverse agonist to prevent DIO will require the optimisation of dosage to ensure that blocking the receptor will not have detrimental effects on the other important actions of ghrelin. An in vitro study in human adipocytes would determine the effect that a physiological range of desacyl and acyl-ghrelin has on lipid retention and would allow for the molecular characterisation of this effect. This will lead to a better understanding of the cellular mechanisms involved, potentially leading to novel treatments for complications associated with atherosclerosis and hypertriglyceridemia. For instance, translating previous findings by Davies and colleagues 49 , is important as it could provide evidence for the speculation that ghrelin immunization may prevent lipid retention within adipocytes. As previously mentioned the resultant fat laden adipocytes could be detrimental and result in the development of T2DM, so in essence we envision that the prevention of lipid accumulation within adipocytes will prevent the indirect immune modulating response that may be leading to insulin resistance and T2DM. In addition, this area of research requires further insight into whether the effect of ghrelin on adipocytes is dependent on acylation of the hormone.
Summary
This review considers the important roles that ghrelin plays in regulating lipolysis, lipogenesis and adipogenesis within adipocytes. However, the studies compared in this review were performed in different species and predominantly in rodents. Further work is essential to understand the role of ghrelin in cellular energy balance within human adipocytes. Current literature report variations in route of administration, dosage and model species, allowing for the potential misinterpretation of ghrelin's physiological role. An expansion of this work using healthy and diseased humans and human cellular models treated with physiological levels of acyl and desacyl-ghrelin will increase our current knowledge of the pathways associated with glucose and lipid metabolism. Human studies will also allow for the elucidation of the therapeutic potential of ghrelin in various metabolic disturbances but in particular, DIO and its complications.
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